DDInter76 DDInter1628
Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxicity and possibly death, amiodarone use should be reserved for its approved indications, according to prescribing information.[L3561,L11265,L11286]
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Amiodarone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Amiodarone {u} (Compound) downregulates {v} (Gene) PRPF4
PRPF4 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Amiodarone {u} (Compound) upregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Amiodarone {u} (Compound) upregulates {v} (Gene) SLC2A6
SLC2A6 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Amiodarone {u} (Compound) downregulates {v} (Gene) NUP88
NUP88 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Amiodarone {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Amiodarone {u} (Compound) downregulates {v} (Gene) PRPF4
PRPF4 {u} (Gene) is regulated by {v} (Gene) LTK
LTK {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Amiodarone {u} (Compound) upregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) regulates {v} (Gene) DUSP4
DUSP4 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Amiodarone {u} (Compound) upregulates {v} (Gene) SLC2A6
SLC2A6 {u} (Gene) is regulated by {v} (Gene) CTCF
CTCF {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Amiodarone {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Nilotinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Amiodarone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Amiodarone (Compound) downregulates PRPF4 (Gene) and PRPF4 (Gene) is upregulated by Ruxolitinib (Compound)
Amiodarone (Compound) upregulates HMGCR (Gene) and HMGCR (Gene) is upregulated by Ruxolitinib (Compound)
Amiodarone (Compound) upregulates SLC2A6 (Gene) and SLC2A6 (Gene) is downregulated by Ruxolitinib (Compound)
Amiodarone (Compound) downregulates NUP88 (Gene) and NUP88 (Gene) is downregulated by Ruxolitinib (Compound)
Amiodarone (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Ruxolitinib (Compound)
Amiodarone (Compound) downregulates PRPF4 (Gene) and PRPF4 (Gene) is regulated by LTK (Gene) and LTK (Gene) is bound by Ruxolitinib (Compound)
Amiodarone (Compound) upregulates HMGCR (Gene) and HMGCR (Gene) regulates DUSP4 (Gene) and DUSP4 (Gene) is upregulated by Ruxolitinib (Compound)
Amiodarone (Compound) upregulates SLC2A6 (Gene) and SLC2A6 (Gene) is regulated by CTCF (Gene) and CTCF (Gene) is upregulated by Ruxolitinib (Compound)
Amiodarone may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)